Cutaneous lymphoproliferative disorders research
Cutaneous lymphoproliferative disorders research is a research topic within Dermatology. Science Explorer counts 20k research works in it since 1950. 12.5% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the classification, staging, treatment, and prognosis of cutaneous lymphomas, with a specific emphasis on mycosis fungoides and Sézary syndrome. It includes discussions on the WHO-EORTC classification, survival outcomes, prognostic factors, and various treatment options such as bexarotene and denileukin diftitox. The cluster also addresses the incidence patterns, genomic landscape, and molecular profiling of cutaneous T-cell lymphomas.
- Cutaneous Lymphomas
- Mycosis Fungoides
- Sézary Syndrome
- EORTC Classification
- T-Cell Lymphoma
- CD30+ Lymphoproliferative Disorders
- Primary Cutaneous Lymphomas
- Bexarotene Treatment
- Prognostic Factors
- Clinical End Points
- Research works
- 20k fractional, since 1950
- In the world top 10%
- 2.5k per year above
- Top-10% rate
- 12.5% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +35% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Cutaneous lymphoproliferative disorders research research?
By volume, the United States and China publish the most (1.1k and 400 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.1k works
- 2 China 400 works
- 3 India 229 works
- 4 Italy 176 works
- 5 Germany 175 works
- 6 France 171 works
- 7 Japan 156 works
- 8 Brazil 154 works
- 9 Spain 139 works
- 10 United Kingdom 114 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Cutaneous lymphoproliferative disorders research research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Cutaneous lymphoproliferative disorders research research, followed by Memorial Sloan Kettering Cancer Center and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer Center United States 41 works
- 2 Memorial Sloan Kettering Cancer Center United States 22 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical College China 18 works
- 4 University of Pennsylvania United States 16 works
- 5 Mayo Clinic in Arizona United States 15 works
- 6 Stanford University United States 14 works
- 7 Yale University United States 14 works
- 8 Harvard University United States 13 works
- 9 Cornell University United States 13 works
- 10 Inserm France 13 works
Who are the leading researchers in Cutaneous lymphoproliferative disorders research?
The most-cited researchers publishing on Cutaneous lymphoproliferative disorders research include Caroline Robert, Thomas Schwarz and Elı́as Campo.
- 1 Caroline Robert 3.3k citations
- 2 Thomas Schwarz 3.1k citations
- 3 Elı́as Campo 3k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Cutaneous lymphoproliferative disorders research research done?
The largest centres of Cutaneous lymphoproliferative disorders research research in 2022–2025 are New York (United States), Beijing (China), Houston (United States) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Houston.
Largest cities, 2022–2025
Where it is the local speciality
- HoustonUS · 58.0 works6.3×
Location quotient: how much more of its research is in Cutaneous lymphoproliferative disorders research than the world average.
Where is the best place to study Cutaneous lymphoproliferative disorders research?
Among universities, judged by research, Thomas Jefferson University, University of Miami and University of Pennsylvania score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Thomas Jefferson University United States | 57.7 | 8.2% | 16.8× | 12 | +247.3% |
| 2 | University of Miami United States | 55.7 | 18.1% | 6.5× | 12 | +128.5% |
| 3 | University of Pennsylvania United States | 46.1 | 13.8% | 4.9× | 16 | +73.9% |
| 4 | Medical University of Vienna Austria | 45.0 | 13.0% | 7.4× | 8 | -7.6% |
| 5 | Icahn School of Medicine at Mount Sinai United States | 44.2 | 11.8% | 6.5× | 12 | +63.9% |
| 6 | Medical University of Warsaw Poland | 43.3 | 0.8% | 12.0× | 10 | +163.5% |
| 7 | Cornell University United States | 43.1 | 14.4% | 3.5× | 13 | +103.8% |
| 8 | University of Bologna Italy | 43.0 | 22.6% | 2.9× | 8 | +37.3% |
| 9 | Harvard University United States | 42.6 | 15.5% | 2.9× | 13 | +45.6% |
| 10 | Stanford University United States | 39.7 | 13.8% | 3.2× | 14 | +56.1% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Cutaneous lymphoproliferative disorders research research growing?
Output in 2018–2022 was 35% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Cutaneous lymphoproliferative disorders research.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.